Clinical trial NCT02453009: Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
Official title: CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostatic Neoplasms
Lead sponsor: Santa Chiara Hospital
Sponsor class: OTHER
First posted: 2015-05-25
Enrollment: 246
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.

Detailed description: CHEIRON trial is a phase II randomized study comparing docetaxel plus enzalutamide to docetaxel alone as first line for castration resistant prostate cancer.

Eligibility criteria: Inclusion Criteria:

1. Histologically- or cytologically-confirmed prostate adenocarcinoma.
2. Metastatic disease.
3. Progressive disease while receiving hormonal therapy or after surgical castration documented by at least one of the following:

   * Increase in measurable disease (RECIST 1.1) \[15\], and/or
   * Appearance of new lesions, including those on bone scan consistent with progressive prostate cancer, and/or
   * Rising PSA defined as 2 sequential increases above a previous lowest reference value. Each value must be obtained at least 1 week apart. A PSA value of at least 2 ng/ml is required at study entry.
   * Effective castration (serum testosterone levels ≤0.50 ng/dL) by orchiectomy and/or LHRH agonists or antagonist with or without anti-androgens.

     i. If the patient has been treated with LHRH agonists or antagonist (i.e., without orchiectomy), then this therapy should be continued.

   ii. If patients were either started on complete androgen blockade, or had a PSA response (defined by any reduction in PSA sustained for at least 3 months) after adding an antiandrogen, prior anti-androgen therapy should be stopped before randomization: at least 6 weeks for bicalutamide and nilutamide, and at least 4 weeks for flutamide, megestrol acetate and any other hormonal therapy.
4. More than 18 years.
5. Eastern Cooperative Oncology Group (ECOG) performance status \<2 (see Appendix 2).
6. Ability to fill the quality of life questionnaire
7. Patient compliance and geographic proximity that allow adequate follow-up.
8. Presence of signed and dated IRB-approved patient informed consent form prior to enrollment into the study.

Exclusion Criteria:

1. Prior chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed \>3 years ago.
2. Prior treatment with abiraterone acetate and/or enzalutamide
3. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy or surgery to the time of randomization. Patients may be on biphosphonates prior to study entry.
4. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to \>30% of bone marrow.
5. History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease.
6. History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke or significant brain trauma). History of loss of consciousness or transient ischemic attack within 12 months of randomization;
7. Inadequate organ and bone marrow function
8. Contraindications to the use of corticosteroid treatment.
9. Clinically significant cardiovascular disease
10. Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
11. Hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene;
12. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which chemotherapy has been completed \>5 years ago and from which the patient has been disease-free for \>5 years.
13. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
14. Any other condition which in the judgment of the investigator would place the subject at undue risk or interfere with the study.

Primary outcomes:
measure: Rate of patients without progression (according to guideline of Prostate Cancer Clinical Trials Working Group 2 - PCWG2)
timeFrame: 6 months after docetaxel first administration
Secondary outcomes:
measure: Rate of objective response according to RECIST criteria
timeFrame: 6 months after docetaxel first administration
measure: Rate of biochemical response according to PCWG2
timeFrame: 6 months after docetaxel first administration
measure: Kaplan-Meier estimates of progression-free survival
timeFrame: 6 months after docetaxel first administration
measure: Kaplan-Meier estimates of overall survival
timeFrame: 6 months after docetaxel first administration
measure: Kaplan-Meier estimates of biochemical progression-free survival
timeFrame: 6 months after docetaxel first administration
measure: Rate of treatment-related mortality
timeFrame: 6 months after docetaxel first administration
measure: Rate of toxicity-related protocol withdrawal
timeFrame: 6 months after docetaxel first administration
measure: Scales of brief pain inventory (BPI)
timeFrame: 6 months after docetaxel first administration
measure: Analgesic score
timeFrame: 6 months after docetaxel first administration
measure: Functional scales and items of FACT - P questionnaire
timeFrame: 6 months after docetaxel first administration
measure: Type and grade of any adverse reaction to treatment, according to CTC-AE v. 4.03
timeFrame: 6 months after docetaxel first administration
Other outcomes:
Locations:
city: Trento
country: Italy
facility: Santa Chiara Hospital
Study officials:
affiliation: Santa Chiara Hospital
name: Orazio Caffo, MD
role: STUDY_CHAIR
References:
citation: Caffo O, Ortega C, Nole F, Gasparro D, Mucciarini C, Aieta M, Zagonel V, Iacovelli R, De Giorgi U, Facchini G, Veccia A, Palesandro E, Verri E, Buti S, Razzini G, Bozza G, Maruzzo M, Ciccarese C, Schepisi G, Rossetti S, Maines F, Kinspergher S, Fratino L, Ermacora P, Nicodemo M, Giordano M, Sartori D, Scapoli D, Sabbatini R, Lo Re G, Morelli F, D'Angelo A, Vittimberga I, Lippe P, Carrozza F, Messina C, Galli L, Valcamonico F, Porta C, Pappagallo G, Aglietta M. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. Eur J Cancer. 2021 Sep;155:56-63. doi: 10.1016/j.ejca.2021.06.016. Epub 2021 Aug 3.